Literature DB >> 12829845

Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1.

Peter Bouma1, Maria Leavitt, Peng Fei Zhang, Igor A Sidorov, Dimiter S Dimitrov, Gerald V Quinnan.   

Abstract

Resistance to neutralization is an important characteristic of primary isolates of human immunodeficiency virus type 1 (HIV-1) that relates to the potential for successful vaccination to prevent infection and use of immunotherapeutics for treatment of established infection. In order to further elucidate mechanisms responsible for neutralization resistance, we studied the molecular mechanisms that determine the resistance of the primary virus isolate of the strain HIV-1 MN to neutralization by soluble CD4 (sCD4). As is the case for the global neutralization resistance phenotype, sCD4 resistance depended upon sequences in the amino-terminal heptad repeat region of gp41 (HR1), as well as on multiple functional interactions within the envelope complex. The functional interactions that determined the resistance included interactions between the variable loop 1 and 2 (V1/V2) region and sequences in or near the CD4 binding site (CD4bs) and with the V3 loop. Additionally, the V3 loop region was found to interact functionally with sequences in the outer domain of gp120, distant from the CD4bs and coreceptor-binding site, as well as with a residue thought to be located centrally in the coreceptor-binding site. These and previous results provide the basis for a model by which functional signals that determine the neutralization resistance, high-infectivity phenotype depend upon interactions occurring across the surface of the gp120 core structure and involving variable loop structures and gp41. This model should be useful in efforts to define epitopes that may be important for primary virus neutralization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829845      PMCID: PMC161940          DOI: 10.1128/jvi.77.14.8061-8071.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  On the historical origins of HIV-1 (MN) and (RF).

Authors:  M S Reitz; H G Guo; J Oleske; J Hoxie; M Popovic; E Read-Connole; P Markham; H Streicher; R C Gallo
Journal:  AIDS Res Hum Retroviruses       Date:  1992-11       Impact factor: 2.205

2.  A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.

Authors:  Peng Fei Zhang; Peter Bouma; Eun Ju Park; Joseph B Margolick; James E Robinson; Susan Zolla-Pazner; Michael N Flora; Gerald V Quinnan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker.

Authors:  F di Marzo Veronese; M S Reitz; G Gupta; M Robert-Guroff; C Boyer-Thompson; A Louie; R C Gallo; P Lusso
Journal:  J Biol Chem       Date:  1993-12-05       Impact factor: 5.157

4.  Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.

Authors:  B A Watkins; M S Reitz; C A Wilson; K Aldrich; A E Davis; M Robert-Guroff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

5.  Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120.

Authors:  J Bagley; P J Dillon; C Rosen; J Robinson; J Sodroski; W A Marasco
Journal:  Mol Immunol       Date:  1994-10       Impact factor: 4.407

6.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

7.  Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.

Authors:  N K Back; L Smit; M Schutten; P L Nara; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain.

Authors:  G Zwart; N K Back; C Ramautarsing; M Valk; L van der Hoek; J Goudsmit
Journal:  AIDS Res Hum Retroviruses       Date:  1994-03       Impact factor: 2.205

9.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more
  13 in total

1.  Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Authors:  Michael B Zwick; Richard Jensen; Sarah Church; Meng Wang; Gabriela Stiegler; Renate Kunert; Hermann Katinger; Dennis R Burton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.

Authors:  Junji Shibata; Kazuhisa Yoshimura; Akiko Honda; Atsushi Koito; Toshio Murakami; Shuzo Matsushita
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

3.  Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.

Authors:  Rong Rong; S Gnanakaran; Julie M Decker; Frederic Bibollet-Ruche; Jesse Taylor; Jeffrey N Sfakianos; John L Mokili; Mark Muldoon; Joseph Mulenga; Susan Allen; Beatrice H Hahn; George M Shaw; Jerry L Blackwell; Bette T Korber; Eric Hunter; Cynthia A Derdeyn
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

4.  Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis.

Authors:  Christine Hager-Braun; Elisabeth O Hochleitner; Miroslaw K Gorny; Susan Zolla-Pazner; Rachelle J Bienstock; Kenneth B Tomer
Journal:  J Am Soc Mass Spectrom       Date:  2010-03-31       Impact factor: 3.109

Review 5.  Germline-targeting immunogens.

Authors:  Leonidas Stamatatos; Marie Pancera; Andrew T McGuire
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

6.  Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization.

Authors:  Xinzhen Yang; Inna Lipchina; Simon Cocklin; Irwin Chaiken; Joseph Sodroski
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

7.  Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Authors:  Rong Rong; Frederic Bibollet-Ruche; Joseph Mulenga; Susan Allen; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.

Authors:  Mei-Yun Zhang; Vidita Choudhry; Igor A Sidorov; Vladimir Tenev; Bang K Vu; Anil Choudhary; Hong Lu; Gabriela M Stiegler; Hermann W D Katinger; Shibo Jiang; Christopher C Broder; Dimiter S Dimitrov
Journal:  J Immunol Methods       Date:  2006-10-16       Impact factor: 2.303

9.  Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.

Authors:  Alexey A Nabatov; Georgios Pollakis; Thomas Linnemann; Aletta Kliphius; Moustapha I M Chalaby; William A Paxton
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.

Authors:  Mei-Yun Zhang; Xiaodong Xiao; Igor A Sidorov; Vidita Choudhry; Fatim Cham; Peng Fei Zhang; Peter Bouma; Michael Zwick; Anil Choudhary; David C Montefiori; Christopher C Broder; Dennis R Burton; Gerald V Quinnan; Dimiter S Dimitrov
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.